Ekso Bionics Holdings
Market Cap
US$30.3m
Last Updated
2020/06/06 07:05 UTC
Data Sources
Company Financials +
Executive Summary
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -32.8% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 2 more risks
Snowflake Analysis
Imperfect balance sheet with concerning outlook.
Similar Companies
Share Price & News
How has Ekso Bionics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EKSO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
35.2%
EKSO
-7.8%
US Medical Equipment
3.8%
US Market
1 Year Return
-73.4%
EKSO
10.9%
US Medical Equipment
9.7%
US Market
Return vs Industry: EKSO underperformed the US Medical Equipment industry which returned 10.9% over the past year.
Return vs Market: EKSO underperformed the US Market which returned 9.7% over the past year.
Shareholder returns
| EKSO | Industry | Market | |
|---|---|---|---|
| 7 Day | 35.2% | -7.8% | 3.8% |
| 30 Day | 46.7% | 2.7% | 11.4% |
| 90 Day | 7.3% | 7.4% | 6.8% |
| 1 Year | -73.4%-73.4% | 11.8%10.9% | 12.1%9.7% |
| 3 Year | -71.7%-71.7% | 58.9%54.6% | 36.2%27.2% |
| 5 Year | -96.3%-96.3% | 106.6%85.3% | 63.7%45.4% |
Price Volatility Vs. Market
How volatile is Ekso Bionics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Type Of Shareholder Owns Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO)?3 months ago | Simply Wall St
US$1.43: That's What Analysts Think Ekso Bionics Holdings, Inc. Is Worth After Its Latest Results4 months ago | Simply Wall St
How Does Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Affect Your Portfolio Volatility?Valuation
Is Ekso Bionics Holdings undervalued compared to its fair value and its price relative to the market?
5.79x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EKSO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EKSO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EKSO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: EKSO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EKSO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EKSO is overvalued based on its PB Ratio (5.8x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is Ekso Bionics Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-32.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EKSO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EKSO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EKSO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EKSO's revenue (14.3% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: EKSO's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EKSO's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Ekso Bionics Holdings performed over the past 5 years?
-3.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EKSO is currently unprofitable.
Growing Profit Margin: EKSO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EKSO is unprofitable, and losses have increased over the past 5 years at a rate of -3.8% per year.
Accelerating Growth: Unable to compare EKSO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EKSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).
Return on Equity
High ROE: EKSO has a negative Return on Equity (-155.22%), as it is currently unprofitable.
Next Steps
Financial Health
How is Ekso Bionics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: EKSO's short term assets ($14.1M) exceed its short term liabilities ($7.6M).
Long Term Liabilities: EKSO's short term assets ($14.1M) exceed its long term liabilities ($4.2M).
Debt to Equity History and Analysis
Debt Level: EKSO's debt to equity ratio (41.5%) is considered high.
Reducing Debt: EKSO's debt to equity ratio has increased from 0.4% to 41.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EKSO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EKSO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.5% each year
Next Steps
Dividend
What is Ekso Bionics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EKSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EKSO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EKSO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EKSO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EKSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Jack Peurach (53yo)
2.25yrs
Tenure
US$660,604
Compensation
Mr. Jack Peurach has been President and Chief Executive Officer at Ekso Bionics Holdings, Inc. since March 9, 2018. Mr. Peurach served as an Executive Vice President of Products at SunPower Corporation sin ...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD660.60K) is about average for companies of similar size in the US market ($USD571.43K).
Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.42yrs | US$100.00k | 0.49% $147.1k | |
| President | 2.25yrs | US$660.60k | 0.089% $27.0k | |
| CFO & Secretary | 1.83yrs | US$397.42k | 0.0054% $1.6k | |
| Chief Commercial Officer | 1.17yrs | no data | no data | |
| President of APAC | 2.42yrs | no data | no data | |
| Managing Director of Ekso Bionics Europe GmbH | 3.58yrs | no data | no data |
2.0yrs
Average Tenure
55yo
Average Age
Experienced Management: EKSO's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.42yrs | US$100.00k | 0.49% $147.1k | |
| President | 2.25yrs | US$660.60k | 0.089% $27.0k | |
| Independent Director | 5.5yrs | US$47.42k | 0.032% $9.6k | |
| Independent Director | 1.58yrs | US$54.81k | 0.040% $12.0k | |
| Independent Director | 6.42yrs | US$58.45k | 0.058% $17.5k | |
| Member of Advisory Council | no data | no data | no data | |
| Member of Advisory Council | no data | no data | no data | |
| Member of Advisory Council | no data | no data | no data | |
| Member of Advisory Council | no data | no data | no data | |
| Member of Advisory Council | no data | no data | no data |
6.4yrs
Average Tenure
62yo
Average Age
Experienced Board: EKSO's board of directors are considered experienced (6.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Top Shareholders
Company Information
Ekso Bionics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ekso Bionics Holdings, Inc.
- Ticker: EKSO
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$30.269m
- Shares outstanding: 5.84m
- Website: https://www.eksobionics.com
Number of Employees
Location
- Ekso Bionics Holdings, Inc.
- 1414 Harbour Way South
- Suite 1201
- Richmond
- California
- 94804
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EKSO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2014 |
| 2300 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2014 |
| 0IFR | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 2014 |
Biography
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. The company’s Ekso device is primarily used in a hospital and rehabilitation setting. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 07:05 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.